Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors

New England Journal of Medicine

Volumn 372, Issue 3, 2015, Pages 211-221

  Weir, Matthew R ^a   Bakris, George L ^b   Bushinsky, David A ^c   Mayo, Martha R ^d   Garza, Dahlia ^d   Stasiv, Yuri ^d   Wittes, Janet ^e   Christ Schmidt, Heidi ^e   Berman, Lance ^d   Pitt, Bertram ^f  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d Relypsa Inc   (United States)

^e University of Iowa   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PATIROMER; PLACEBO; POTASSIUM; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; POLYMER;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; SUPRAVENTRICULAR PREMATURE BEAT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; COMPLICATION; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POLYMERS; POTASSIUM; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SECONDARY PREVENTION; SINGLE-BLIND METHOD;

EID: 84920982556     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1410853     Document Type: Article

References (33)

1. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169:1156-62.
2. Yildirim T, Arici M, Piskinpasa S, et al. Major barriers against renin-angiotensinaldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Ren Fail 2012;34: 1095-9.
3. Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658-65.
4. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585-92.
5. Cheng ES, Stringer KM, Pegg SP. Colonic necrosis and perforation following oral sodium polystyrene sulfonate (Resonium A/Kayexalate) in a burn patient. Burns 2002;28:189-90.
6. Minford EJ, Hand T, Jones MC. Constipation and colonic perforation complicating calcium resonium therapy. Postgrad Med J 1992;68:302.
7. Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis 1992;20:159-61.
8. McGowan CE, Saha S, Chu G, Resnick MB, Moss SF. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J 2009;102:493-7.
9. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010;21: 733-5.
10. Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 2013; 126(3):264. e9-264. e24.
11. Buysse JM, Huang IZ, Pitt B. PEARLHF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 2012;8:17-28.
12. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:Suppl 1: S1-S290.
13. O'Brien PC, Zhang D, Bailey KR. Semiparametric and non-parametric methods for clinical trials with incomplete data. Stat Med 2005;24:341-58.
14. Erratum, Stat Med 2005;24:3385.
15. Hodges JL, Lehmann EL. Rank methods for combination of independent experiments in analysis of variance. Ann Math Stat 1962;33:482-97.
16. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
17. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787-847.
18. Erratum, Eur Heart J 2013; 34:158.
19. Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013;62:1585-93.
20. Rossignol P, Dobre D, McMurray JJV, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014;7:51-8.
21. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010;5:531-48.
22. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensinconverting enzyme inhibitors: how much should we worry? Arch Intern Med 1998; 158:26-32.
23. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014;34:333-9.
24. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-903.
25. Berlyne GM, Janabi K, Shaw AB. Dangers of resonium A in the treatment of hyperkalemia in renal failure. Lancet 1966; 1:167-9.
26. Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci 2014;347:93-100.
27. Mikrut M, Brockmiller-Sell H. Sodium polystyrene sulfonate dosing guidelines for the treatment of adult hyperkalemia. Hosp Pharm 2004;39:765-71.
28. Scherr L, Ogden DA, Mead AW, Spritz N, Rubin AL. Management of hyperkalemia with a cation-exchange resin. N Engl J Med 1961;264:115-9.
29. Kessler C, Ng J, Valdez K, Xie H, Geiger B. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med 2011;6:136-40.
30. Gruy-Kapral C, Emmett M, Santa Ana CA, Porter JL, Fordtran JS, Fine KD. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 1998;9:1924-30.
31. Sandal S, Karachiwala H, Noviasky J, Wang D, Elliott WC, Lehmann DF. To bind or to let loose: effectiveness of sodium polystyrene sulfonate in decreasing serum potassium. Int J Nephrol 2012;2012: 940320.
32. Chernin G, Gal-Oz A, Ben-Assa E, et al. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensinaldosterone system inhibition therapy. Clin Cardiol 2012;35:32-6.
33. Chaaban A, Abouchacra S, Gebran N, et al. Potassium binders in hemodialysis patients: a friend or foe? Ren Fail 2013;35: 185-8.